Abstract
Background: To determine expression levels of urokinase-type plasminogen activator (uPA), soluble urokinase-type plasminogen activator receptor (suPAR), plasminogen activator inhibitor-1 (PAI-1) in plasma and to identify gene polymorphisms specific to patients with pelvic inflammatory disease (PID) and healthy controls. Methods: Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were used to measure plasma levels and polymorphisms in uPA, suPAR, and PAI-1 among seventy healthy controls and 64 PID patients before and after they received routine treatment protocols. Results: The levels of plasma uPA (ng/ml) and soluble suPAR (pg/ml) were significantly increased in PID patients (uPA: 0.57 ± 0.03; suPAR: 1372.04 ± 68.20) when compared to that in normal controls (uPA: 0.55 ± 0.06, p = 0.002; suPAR: 1192.46 ± 51.98, p = 0.04); moreover, suPAR decreased significantly after treatment when compared to levels noted in the same patients (1220.06 ± 58.14; p = 0.003) after they received treatment. The increased expression of suPAR was significantly correlated with WBC counts (r = 0.382, p = 0.002, n = 64) in blood as well as the plasma levels of CRP (r = 0.441, p.
| Original language | English |
|---|---|
| Pages (from-to) | 138-144 |
| Number of pages | 7 |
| Journal | Clinica Chimica Acta |
| Volume | 415 |
| DOIs | |
| Publication status | Published - Jan 16 2013 |
| Externally published | Yes |
Fingerprint
Keywords
- Pelvic inflammatory disease
- Polymorphism
- Soluble urokinase-type plasminogen activator receptor
- Urokinase-type plasminogen activator
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Biochemistry, medical
Cite this
Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease. / Yeh, Yuan Hung; Wang, Po Hui; Lin, Long Yau; Tee, Yi Torng; Chou, Ming Chih; Yang, Shun Fa; Tsai, Hsiu Ting.
In: Clinica Chimica Acta, Vol. 415, 16.01.2013, p. 138-144.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease
AU - Yeh, Yuan Hung
AU - Wang, Po Hui
AU - Lin, Long Yau
AU - Tee, Yi Torng
AU - Chou, Ming Chih
AU - Yang, Shun Fa
AU - Tsai, Hsiu Ting
PY - 2013/1/16
Y1 - 2013/1/16
N2 - Background: To determine expression levels of urokinase-type plasminogen activator (uPA), soluble urokinase-type plasminogen activator receptor (suPAR), plasminogen activator inhibitor-1 (PAI-1) in plasma and to identify gene polymorphisms specific to patients with pelvic inflammatory disease (PID) and healthy controls. Methods: Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were used to measure plasma levels and polymorphisms in uPA, suPAR, and PAI-1 among seventy healthy controls and 64 PID patients before and after they received routine treatment protocols. Results: The levels of plasma uPA (ng/ml) and soluble suPAR (pg/ml) were significantly increased in PID patients (uPA: 0.57 ± 0.03; suPAR: 1372.04 ± 68.20) when compared to that in normal controls (uPA: 0.55 ± 0.06, p = 0.002; suPAR: 1192.46 ± 51.98, p = 0.04); moreover, suPAR decreased significantly after treatment when compared to levels noted in the same patients (1220.06 ± 58.14; p = 0.003) after they received treatment. The increased expression of suPAR was significantly correlated with WBC counts (r = 0.382, p = 0.002, n = 64) in blood as well as the plasma levels of CRP (r = 0.441, p.
AB - Background: To determine expression levels of urokinase-type plasminogen activator (uPA), soluble urokinase-type plasminogen activator receptor (suPAR), plasminogen activator inhibitor-1 (PAI-1) in plasma and to identify gene polymorphisms specific to patients with pelvic inflammatory disease (PID) and healthy controls. Methods: Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were used to measure plasma levels and polymorphisms in uPA, suPAR, and PAI-1 among seventy healthy controls and 64 PID patients before and after they received routine treatment protocols. Results: The levels of plasma uPA (ng/ml) and soluble suPAR (pg/ml) were significantly increased in PID patients (uPA: 0.57 ± 0.03; suPAR: 1372.04 ± 68.20) when compared to that in normal controls (uPA: 0.55 ± 0.06, p = 0.002; suPAR: 1192.46 ± 51.98, p = 0.04); moreover, suPAR decreased significantly after treatment when compared to levels noted in the same patients (1220.06 ± 58.14; p = 0.003) after they received treatment. The increased expression of suPAR was significantly correlated with WBC counts (r = 0.382, p = 0.002, n = 64) in blood as well as the plasma levels of CRP (r = 0.441, p.
KW - Pelvic inflammatory disease
KW - Polymorphism
KW - Soluble urokinase-type plasminogen activator receptor
KW - Urokinase-type plasminogen activator
UR - http://www.scopus.com/inward/record.url?scp=84868645090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868645090&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2012.10.038
DO - 10.1016/j.cca.2012.10.038
M3 - Article
VL - 415
SP - 138
EP - 144
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
ER -